摘要
呋喹替尼(Fruquintinib)是一种新型且具有高度选择性的血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)抑制剂,在结直肠癌(colorectal cancer,CRC)综合治疗中发挥着重要作用。研究显示,呋喹替尼能够有效阻断肿瘤血管生成,并在转移性CRC治疗中展现了显著疗效和良好的耐受性。文章综述了呋喹替尼的药理作用机制、药代动力学特征、临床试验情况以及药物常见的不良反应和处理措施。同时,文章还探讨了VEGFR抑制剂与其他疗法的联合应用潜力,为进一步优化呋喹替尼在CRC个体化治疗中的应用提供了新的方向。
Fruquintinib is a novel and highly selective inhibitor of vascular endothelial growth factor receptor(VEGFR),which plays an important role in the comprehensive treatment of colorectal cancer(CRC).Numerous studies have shown that fruquintinib can effectively block tumor angiogenesis and has demonstrated significant efficacy and good tolerance in the treatment of metastatic CRC.This review aims to summarize and discuss the pharmacological mechanism,pharmacokinetic characteristics,adverse event of fruquintinib,as well as the results of a series of clinical trials in CRC.Additionally,this review explores the potential of combining VEGFR inhibitors with other therapies,providing new directions for further optimizing its use in personalized treatment.
作者
谢烨杰
秦紫恒
杨朝纲
XIE Yejie;QIN Ziheng;YANG Chaogang(The Second Clinical School,Wuhan University,Wuhan,430071,China;Department of Gastrointestinal Surgery,Zhongnan Hospital of Wuhan University,Wuhan,430071,China;Hubei Key Laboratory of Tumour Biological Behaviours,Zhongnan Hospital of Wuhan University,Wuhan,430071,China;Hubei Cancer Clinical Study Centre,Zhongnan Hospital of Wuhan University,Wuhan,430071,China;The Clinical Medical Research Centre of Peritoneal Cancer of Wuhan,Zhongnan Hospital of Wuhan University,Wuhan,430071,China)
出处
《医学分子生物学杂志》
2025年第5期500-507,共8页
Journal of Medical Molecular Biology
基金
武汉市腹膜癌临床医学研究中心资助项目(No.2015060911020462)
武汉大学中南医院“优秀中青年人才培养计划”(No.ZNYQ2023003)
武汉大学中南医院科技创新培育基金(No.CXPY2020025)。
关键词
呋喹替尼
结直肠癌
血管内皮生长因子
临床试验
副反应
fruquintinib
colorectal cancer
vascular endothelial growth factor
clinical trial
adverse event
